Core Insights - GenScript Biotech Corporation reported strong financial results for FY2025, with revenue reaching approximately US$959.5 million, a 61.4% increase year-on-year, and adjusted net profit rising to US$230.3 million, reflecting a 285.0% growth [2][4][6]. Group Performance - The company achieved a gross profit of approximately US$553.2 million, up 103.3% from US$272.1 million in 2024, driven by revenue expansion, particularly in biologics development services [5]. - Selling and distribution expenses increased by 12.9% to approximately US$99.5 million, attributed to the expansion of commercial teams and investments in regional operations [7]. - Administrative expenses rose by 12.4% to approximately US$128.6 million, mainly due to capacity expansion and initial expenses for a new site [8]. - R&D expenses increased by 32.4% to approximately US$71.2 million, driven by recruitment of skilled professionals and expansion of research initiatives [9]. Strategic Drivers of FY2025 Performance - Integrated platform synergies contributed approximately 65% of the revenue growth for the GenScript Life Science Group (LSG) [11]. - The company strengthened its global reach, with Europe and Asia-Pacific showing significant revenue growth of 29% and 33% year-on-year, respectively [12]. - GenScript advanced proprietary technologies and product platforms, enhancing differentiation and customer adoption in high-growth applications [13]. - Automation and digitalization efforts improved operational efficiency, with 60% of global production capacity expected to be powered by AI-driven automation by the end of 2026 [14]. Business Segment Highlights - GenScript Life Science Group generated US$522.1 million in revenue, up 14.8% year-on-year, benefiting from strong demand and adoption of its integrated gene-to-protein platform [15]. - ProBio experienced exceptional growth, with revenue reaching US$388.7 million, a 309.1% increase year-on-year, and secured multiple drug development projects [16]. - Bestzyme generated US$58.0 million in revenue, up 7.9% year-on-year, driven by advancements in industrial biotechnology and AI-enabled R&D capabilities [17]. Outlook - For 2026, GenScript anticipates continued growth driven by rising demand for integrated biotechnology platforms and advanced therapeutics development, with projected revenue growth rates of 10%-15% for Bestzyme, 20%-25% for ProBio, and 15%-18% for GenScript LSG [23].

Core Insights - Twist Bioscience reported a strong first-quarter performance for fiscal 2026, with revenue reaching $103.7 million, reflecting a 17% year-over-year growth and marking the 12th consecutive quarter of revenue growth [5][4]. - The growth was significantly driven by demand for AI-enabled discovery, with over $25 million in orders specifically tied to this area booked for fiscal 2025 [1][5]. - The company aims for adjusted EBITDA break-even by the fourth quarter of fiscal 2026, while also increasing operating expenses to support growth [13][5]. Financial Performance - DNA synthesis and protein solutions (DSPS) revenue increased to $51.1 million, up 27% year-over-year [1]. - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million compared to the prior-year quarter [3]. - Gross margin was reported at 52.0%, higher than expected, attributed to revenue growth and process improvements [4]. Market Trends - The company is expanding its services beyond DNA synthesis to include protein expression and antibody characterization, targeting large pharma, tech companies, and well-funded biotechs [6]. - NGS applications revenue was approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [7]. - Therapeutics revenue increased to approximately $37.2 million, up 39% year-over-year, driven by greater uptake from large pharma and biotech [15]. Guidance and Outlook - Twist raised its full-year revenue outlook to $435 million to $440 million, indicating about 16% growth at the midpoint [12]. - For the second quarter, the company expects revenue of $107 million to $108 million, also reflecting about 16% growth at the midpoint [12]. - Management expressed confidence in continued growth in NGS driven by key accounts and partnerships [9][10]. Geographic and Sector Performance - Revenue by geography showed growth in the Americas ($58.4 million), EMEA ($38.4 million), and APAC ($7.0 million) compared to the previous year [11]. - Global supply partner revenue rose to $12.8 million, a 50% increase, attributed to new partnerships and growth among diagnostics OEM partners [11]. - Academic research and government revenue remained flat at approximately $12.2 million, with expectations for growth in the second quarter due to increased confidence in NIH funding [15].